iA Global Asset Management Inc. Buys 8,664 Shares of Johnson & Johnson $JNJ

Key Points

• iA Global Asset Management increased its Johnson & Johnson stake by 2.4% in the first quarter, buying 8,664 additional shares and bringing its total holdings to 371,110 shares worth about $90.7 million.
• Wall Street sentiment remains constructive on J&J, with 20 analysts rating it a Buy, seven Hold ratings, and a consensus price target of $256.70.
• Johnson & Johnson recently beat first-quarter expectations with EPS of $2.70 on revenue of $24.06 billion, and it also raised its quarterly dividend to $1.34 per share from $1.30.

iA Global Asset Management Inc. lifted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 371,110 shares of the company's stock after buying an additional 8,664 shares during the period. Johnson & Johnson comprises 1.3% of iA Global Asset Management Inc.'s investment portfolio, making the stock its 16th largest position. iA Global Asset Management Inc.'s holdings in Johnson & Johnson were worth $90,714,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Auto Owners Insurance Co grew its holdings in Johnson & Johnson by 22,225.6% in the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares during the last quarter. Norges Bank bought a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $6,924,523,000. Capital World Investors purchased a new position in shares of Johnson & Johnson in the 4th quarter worth about $2,005,942,000. Diamant Asset Management Inc. lifted its position in Johnson & Johnson by 24,436.5% in the 1st quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company's stock valued at $109,338,000 after acquiring an additional 4,454,778 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Johnson & Johnson by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company's stock valued at $49,740,362,000 after acquiring an additional 3,731,074 shares during the period. 69.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on JNJ. Guggenheim raised their target price on Johnson & Johnson from $266.00 to $270.00 and gave the stock a "buy" rating in a research report on Friday, June 26th. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $225.00 to $251.00 and gave the stock a "market perform" rating in a report on Wednesday, April 15th. Leerink Partners raised shares of Johnson & Johnson from a "market perform" rating to an "outperform" rating and set a $265.00 price target on the stock in a research note on Wednesday, May 13th. Morgan Stanley set a $283.00 price objective on Johnson & Johnson in a research note on Wednesday, April 15th. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $265.00 target price on shares of Johnson & Johnson in a report on Wednesday, April 15th. Twenty research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $256.70.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $262.52 on Friday. Johnson & Johnson has a 12 month low of $154.21 and a 12 month high of $263.10. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The firm has a market cap of $631.93 billion, a P/E ratio of 30.35, a P/E/G ratio of 2.58 and a beta of 0.24. The stock's fifty day moving average price is $233.72 and its 200-day moving average price is $231.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.02. The firm had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company's quarterly revenue was up 9.9% on a year-over-year basis. During the same period last year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities research analysts expect that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend was Tuesday, May 26th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.30. Johnson & Johnson's payout ratio is presently 61.97%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Members of Congress have been buying J&J shares, which can signal confidence in the company’s prospects and may attract attention from retail investors. Members of Congress Are Loading Up on Johnson & Johnson and UnitedHealth. Here's Why Retail Investors Should Pay Attention.
• Positive Sentiment: Johnson & Johnson launched its Dual-Energy THERMOCOOL SMARTTOUCH SF cardiac ablation platform in Europe, adding a commercial growth catalyst in its medtech business. Johnson & Johnson (JNJ) Launches Dual-Energy Cardiac Ablation Catheter in Europe
• Positive Sentiment: J&J is being highlighted as a top dividend and defensive healthcare name, with articles pointing to its reliable cash flow, dividend profile, and long-term appeal. Johnson & Johnson (JNJ): Focused on Cancer and Neuroscience as a Top Dividend Aristocrat Stock to Buy
• Positive Sentiment: Recent updates say J&J is strengthening its cancer pipeline, including European progress for Tecvayli in combination with Darzalex and an acquisition of Firefly Bio to expand oncology research. Johnson & Johnson (JNJ) Expands Cancer Pipeline As Talc Verdict Eases One Risk
• Neutral Sentiment: Several market commentary pieces reiterated bullish Wall Street views and compared J&J favorably with AbbVie, supporting the stock’s valuation narrative but not adding a major new catalyst. Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street's Bullish Views?
• Neutral Sentiment: J&J was also featured in dividend-income and portfolio articles, which helps reinforce its reputation as a stable income stock, though these pieces are unlikely to move shares much on their own. J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?
• Negative Sentiment: No major negative company-specific headline stood out in the latest set of articles; the closest risk item is that ongoing litigation remains a background concern, even as one recent talc verdict went J&J’s way. Johnson & Johnson (JNJ) Expands Cancer Pipeline As Talc Verdict Eases One Risk

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the company's stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares of the company's stock, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.